stella
beta
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors — Stella
Recruiting
Back to Clear Cell Renal Cell Cancer (ccRCC) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(10 sites)
Australia
Peter MacCallum Cancer Centre, Melbourne
UNSW Sydney, St Vincent's Hospital Sydney, Sydney
France
Centre Jean Perrin, Clermont-Ferrand
Centre Georges François Leclerc, Dijon
CHU de Grenoble-Alpes, Boulevard de la Chantourne, Grenoble
Show all 10 locations
View full record on ClinicalTrials.gov